Products - Thyroid disorders | Topic | NICE

Showing 4 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Cabozantinib for treating medullary thyroid cancer (TA516)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Thyroid disease: assessment and management (NG145)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
12 October 2023
Published:
20 November 2019
Vandetanib for treating medullary thyroid cancer (TA550)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2018